PA41-BMD: Clinical Chemistry Summary

DTTID: 108-020-004-000-5
Study Number: 108020004
Study Type: 5-Day Toxicity
Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: 1,4-Dichlorobenzene
CAS Number: 106-46-7
DTXSID: DTXSID1020431

Date: 20 Jun 2025
Time: 9:00:15 AM

Female Clinical Chemistry Data and BMD Values

	Treatment Groups (ppm) & BMD Values (ppm)								
	0	1	10	50	150	400	800	BMD_{1Std}	$BMDL_{1Std}$
Cholesterol (mg/dL)	91.7 ± 4.2[10]**	92.4 ± 2.2[5]	96.0 ± 6.5[5]	99.0 ± 8.1[5]	105.2 ± 4.3[5]	111.0 ± 4.6[5]*	143.2 ± 5.3[5]**	259.4	126.2
Sorbitol Dehydrogenase (IU/L)	10.2 ± 0.6[10]*	13.1 ± 3.1[5]	9.7 ± 0.6[5]	9.4 ± 1.3[5]	10.6 ± 2.6[5]	40.4 ± 23.7[5]	23.6 ± 1.5[5]*	NVM	NVM
Triglycerides (mg/dL)	54.9 ± 3.6[10]**	75.6 ± 5.2[5]	69.0 ± 7.1[5]	73.6 ± 9.4[5]	62.2 ± 8.1[5]	70.0 ± 6.4[5]	112.8 ± 10.4[5]**	489.4	332.3

Values given as mean ± SEM [N].
Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.
Statistical significance for the control group indicates a significant trend test.
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.
* Statistically significant at p <= 0.05
** Statistically significant at p <= 0.01
BMD_{1Std} and $BMDL_{1Std}$: Benchmark response (BMR) set at 1 standard deviation from the mean.
NVM = no viable model

** END OF REPORT **